Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Experts discuss results and implications from 3 of the key studies in acute myeloid leukemia and chronic myeloid leukemia from the virtual Hematology 2020 meeting, including magrolimab in AML, the STAMP inhibitor asciminib in CML (the ASCEMBL trial), and optimal dosing for ponatinib in CML (the OPTIC trial).
Jorge Cortes, MD
Eunice S. Wang, MD
Released: February 26, 2021

In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include:  

  • The macrophage immune checkpoint inhibitor magrolimab in AML
  • The STAMP inhibitor asciminib in CML (the ASCEMBL trial)
  • Optimal dosing for the TKI ponatinib in CML


Jorge Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
Augusta, Georgia

Eunice S. Wang, MD
Professor, Oncology
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Epizyme Inc.
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Sagar Lonial, MD; Suzanne Lentzsch, MD, PhD; and Thomas G. Martin, MD discuss the use of BCMA-targeted agents in relapsed/refractory multiple myeloma in an on-demand webcast, from Clinical Care Options (CCO)

Sagar Lonial, MD
Program Director
Suzanne Lentzsch, MD, PhD Thomas G. Martin, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: October 15, 2021 Expired: October 14, 2022

Patient-friendly resource on myelodysplastic syndromes from Clinical Care Options (CCO)

person default Sara Tinsley, PhD, ARNP, AOCN Released: October 15, 2021

Download this short summary slideset on myelodysplastic syndromes to help diagnose and manage your patients, from Clinical Care Options (CCO).

Amy E. DeZern, MD, MHS Daniel Pollyea, MD, MS Amer Zeidan, MBBS Released: October 12, 2021

Expert commentary on the pharmacist’s role in caring for CAR T-cell therapy recipients, from Clinical Care Options (CCO)

Zahra Mahmoudjafari, PharmD, BCOP, DPLA Released: October 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.